These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16471066)

  • 21. [Diagnostics and drug therapy of multiple sclerosis].
    Suomen Neurologinen Yhdistys ry
    Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
    [No Abstract]   [Full Text] [Related]  

  • 22. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
    Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
    Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?
    Hodgkinson SJ
    J Clin Neurosci; 2001 Jul; 8(4):378-9. PubMed ID: 11437587
    [No Abstract]   [Full Text] [Related]  

  • 24. Multiple sclerosis- diagnosis, management and prognosis.
    Tsang BK; Macdonell R
    Aust Fam Physician; 2011 Dec; 40(12):948-55. PubMed ID: 22146321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon? The case against.
    Macdonell R
    J Clin Neurosci; 2001 Jul; 8(4):379-81. PubMed ID: 11437588
    [No Abstract]   [Full Text] [Related]  

  • 26. The treatment of multiple sclerosis with beta-interferon.
    Poser CM
    Neuroepidemiology; 2008; 31(3):157-8. PubMed ID: 18716413
    [No Abstract]   [Full Text] [Related]  

  • 27. The REFLEX study: a missed opportunity?
    Giovannoni G
    Lancet Neurol; 2012 Jan; 11(1):22-4. PubMed ID: 22146410
    [No Abstract]   [Full Text] [Related]  

  • 28. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vogt-Koyanagi-Harada syndrome in a case of multiple sclerosis.
    Montero JA; Sanchis ME; Fernandez-Munoz M
    J Neuroophthalmol; 2007 Mar; 27(1):36-40. PubMed ID: 17414871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Beta interferon and multiple sclerosis].
    Kinnunen E
    Duodecim; 1996; 112(24):2368-73. PubMed ID: 10605237
    [No Abstract]   [Full Text] [Related]  

  • 33. Fixed drug eruption with interferon-beta-1b.
    Tai YJ; Tam M
    Australas J Dermatol; 2005 Aug; 46(3):154-7. PubMed ID: 16008645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
    Walther EU; Dietrich E; Hohlfeld R
    Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple sclerosis and systemic sclerosis: efficacy of interferon beta on skin lesions.
    Carrieri PB; Petracca M; Montella S; Delfino M; Sepe C; Gattoni A
    Ann Rheum Dis; 2008 Aug; 67(8):1192-3. PubMed ID: 18621969
    [No Abstract]   [Full Text] [Related]  

  • 36. [Activation of psoriasis in patients undergoing treatment with interferon-beta].
    Navne JE; Hedegaard U; Bygum A
    Ugeskr Laeger; 2005 Aug; 167(32):2903-4. PubMed ID: 16109199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Guidelines of the consensus conference on multiple sclerosis].
    French Federation of Neurology, with participation of l'AEAES.
    Rev Neurol (Paris); 2001 Jul; 157(6-7):713-21. PubMed ID: 11458194
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment modification in multiple sclerosis: classifications, alternatives, and the outcomes].
    Cendrowski W
    Neurol Neurochir Pol; 2007; 41(4):365-8. PubMed ID: 18027457
    [No Abstract]   [Full Text] [Related]  

  • 40. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.